Perosphere lands fast track status for its anticoagulant reversal agent PER977
By Michael Fitzhugh
Thursday, April 2, 2015
Perosphere Inc., a private company focused on bringing a broadly applicable anticoagulant reversal agent to market, has won FDA fast track status for the synthetic small molecule ahead of planned phase III studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.